CRISPR Therapeutics AG
CRSPNasdaqCIK 1674416HealthcareFiscal year ends Dec 31
Reports and events: 206 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-11-0216:10 ET | 10-Q | Quarterly reportPeriod 2026-09-30 | 0001193125-26-443665 |
| 2026-11-0216:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-443644 |
| 2026-10-1916:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-425243 |
| 2026-08-0316:31 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-330672 |
| 2026-08-0316:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-330644 |
| 2026-06-0416:45 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257593 |
| 2026-05-0416:48 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-204188 |
| 2026-05-0416:41 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-204147 |
| 2026-04-2108:05 ET | DEF 14A | Proxy statementPeriod 2026-06-04 | 0001193125-26-165158 |
| 2026-03-1616:06 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-108333 |
| 2026-03-1107:07 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-101073 |
| 2026-02-1216:59 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-048957 |
| 2026-02-1216:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-048873 |
| 2026-01-1208:44 ET | 8-K | 8.01 Other events | 0001193125-26-009880 |
| 2025-11-1008:15 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-273337 |
| 2025-11-1008:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-273329 |
| 2025-10-1516:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-240282 |
| 2025-08-0416:30 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-102052 |
| 2025-08-0416:21 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-102027 |
| 2025-06-2607:08 ET | 8-K | 8.01 Other events | 0000950170-25-090170 |
| 2025-06-0916:33 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-083799 |
| 2025-05-1916:36 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-074428 |
| 2025-05-0616:10 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-064468 |
| 2025-05-0616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-064435 |
| 2025-04-1616:05 ET | DEF 14A | Proxy statementPeriod 2025-06-05 | 0000950170-25-054711 |
| 2025-03-2616:12 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-045232 |
| 2025-02-1116:10 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-017899 |
| 2025-02-1116:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-017879 |
| 2024-11-0509:10 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-121105 |
| 2024-11-0509:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-121103 |
| 2024-08-0516:10 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-090746 |
| 2024-08-0516:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-090727 |
| 2024-06-0308:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-067660 |
| 2024-05-2308:14 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950123-24-005877 |
| 2024-05-0816:20 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-055719 |
| 2024-05-0816:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055689 |
| 2024-04-0916:42 ET | DEF 14A | Proxy statementPeriod 2024-05-30 | 0000950170-24-043025 |
| 2024-02-2107:50 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-017571 |
| 2024-02-2107:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-017568 |
| 2024-02-1317:22 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-24-033973 |
| 2024-02-1306:30 ET | 8-K | 8.01 Other events | 0001193125-24-032825 |
| 2024-01-1616:11 ET | 8-K | 8.01 Other events | 0000950170-24-004616 |
| 2023-12-1916:23 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-23-071505 |
| 2023-12-1508:58 ET | 8-K | 8.01 Other events | 0000950170-23-070582 |
| 2023-12-1309:22 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-23-069892 |
| 2023-12-0813:16 ET | 8-K | 8.01 Other events | 0000950170-23-068974 |
| 2023-12-0416:26 ET | 8-K | 8.01 Other events | 0000950170-23-067774 |
| 2023-11-1607:21 ET | 8-K | 8.01 Other events | 0000950170-23-064341 |
| 2023-11-0616:42 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-059476 |
| 2023-11-0616:33 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-059461 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 2, 2026, 20:24 ET. Listed shows no prices and gives no investment advice.